PROGRAM CHAIRS
Nipa R. Shah, MD
Professor & Chair
Department of Community Health and Family Medicine
University of Florida
Jacksonville, FL
Muthiah Vaduganathan, MD, MPH
Co-Director
Center for Cardiometabolic Implementation Science
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
PROGRAM OVERVIEW
This innovative educational symposium shares a combination of didactic lecture and simulation case challenges tailored to enhance the clinician knowledge of SGLT2 inhibitors and GLP-1 RAs in the management of heart failure and chronic kidney disease. With a focus on evidence-based, and holistic patient care, this program strives to improve communication among multidisciplinary care team members to optimize patient care.
TARGET AUDIENCE
This educational activity is designed to meet the needs of healthcare providers (HCPs) who have a role in the diagnosis and treatment of patients with cardiometabolic diseases (CMDs), namely type 2 diabetes (T2DM), chronic kidney disease (CKD), and heart failure (HF). The multidisciplinary team (MDT) members for which this activity is intended include primary care physicians (PCPs; including hospitalists), endocrinologists, associated advanced practice providers (APPs; including physician assistants and nurse practitioners), pharmacists, and certified diabetes educators.
LEARNING OBJECTIVES
Healthcare professionals that manage patients with CKD and HF:
- Formulate strategies to promptly identify and diagnose patients with CDK or HF or those at risk for disease progression
- Integrate evidence-based guidelines for managing CKD and HF based on the latest evidence for SGLT2i and GLP-1 RA agents and patient-specific factors
- Discuss the clinical efficacy and tolerability profiles of approved novel and investigational agents for the treatment of CKD and HF
Healthcare professionals that provide care for the overall management of cardio-renal-comorbid conditions:
- Implement a holistic, patient-centric care approach that streamlines communication across a multi-disciplinary care team to reduce current barriers to optimally managing patients with cardio-renal-metabolic comorbidities, including T2D, HF, and CKD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
AAFP ACCREDITATION
This activity is acceptable for up to 1.25 Elective credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Nipa Shah, MD | Has nothing to disclose. |
| Muthiah Vaduganathan, MD, MPH | Reports that he has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Fresenius Medical Care, Idorsia Pharmaceuticals, Lexicon Pharmaceuticals, Merck, Milestone Pharmaceuticals, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health; and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed Pharmaceuticals, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sireesha Murala, MD, Medical Director for Med Learning Group, has nothing to disclose.
- Joan Duer-Hefele, RN, Mam CRCC, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 11, 2024
EXPIRATION DATE: October 11, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
